3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Colorectal Neoplasms
450
Stomach Neoplasms
295
Rectal Neoplasms
271
Colonic Neoplasms
192
Pancreatic Neoplasms
177
Neoplasm Metastasis
94
Esophageal Neoplasms
88
Carcinoma, Hepatocellular
60
Adenocarcinoma Of Esophagus
47
Cholangiocarcinoma
46
Neoplasms
42
Biliary Tract Neoplasms
38
Gallbladder Neoplasms
31
Adenocarcinoma
30
Gastrointestinal Neoplasms
29
Liver Neoplasms
25
Esophageal Squamous Cell Carcinoma
23
Carcinoma, Non-Small-Cell Lung
18
Bile Duct Neoplasms
17
Parkinson Disease 4, Autosomal Dominant Lewy Body
13
Locally Advanced Rectal Cancer
13
Colorectal Cancer Metastatic
11
Appendiceal Neoplasms
11
Recurrence
10
Peritoneal Neoplasms
10
Ovarian Neoplasms
9
Carcinoma
7
Breast Neoplasms
7
Neurotoxicity Syndromes
6
Gastrointestinal Diseases
6
Interventions
durvalumab
2
Nivolumab
2
Gemcitabine
2
tremelimumab
1
regorafenib
1
nilotinib
1
neratinib
1
encorafenib
1
Valproic Acid
1
Taxes
1
Standard of Care
1
Radiomics
1
Practice Guidelines as Topic
1
Palliative Care
1
Oxaliplatin
1
Leucovorin
1
Hepatectomy
1
Folfox protocol
1
Fluorouracil
1
Clinical Trials, Phase II as Topic
1
Clinical Trials, Phase I as Topic
1
Clinical Trials as Topic
1
Cisplatin
1
Cetuximab
1
AZD 6244
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Disease Progression
×
Oxaliplatin
×
Gastrointestinal
×
Clear all
NCT05712356
2026-05-26
BOLSTER
Lisata Therapeutics, Inc.
Phase 2
Terminated
66 enrolled
12 charts